-
公开(公告)号:US07807678B2
公开(公告)日:2010-10-05
申请号:US10776419
申请日:2004-02-10
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
IPC分类号: A61K31/497 , C07D241/36 , C07D403/06 , C07D241/04 , C07D295/02
CPC分类号: C07D487/04 , A61K38/12 , C07D207/16 , C07D241/04 , C07D241/08 , C07D317/72 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/12 , C07K5/0202 , C07K5/021 , C07K5/06078 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0823 , C07K5/0827 , C07K5/1008 , C07K5/101 , G06F19/16 , G06F19/706
摘要: The invention relates to a method of deriving a peptidomimetic of a biologically active metallopeptide, wherein the peptidomimetic includes at least one non-peptide ring structure defining a template space superimposable on a corresponding defined template space of the metallopeptide, and where the peptidomimetic further includes at least two elements independently including an amino acid residue, amino acid side chain moiety or derivative thereof, the elements defining and occupying a similar descriptor space as corresponding elements of the metallopeptide. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5- and 6-5-bicyclic fused ring structure melanocortin receptor-specific peptidomimetics.
摘要翻译: 本发明涉及一种衍生生物活性金属肽的拟肽的方法,其中拟肽包括至少一个限定模板空间的非肽环结构,该模板空间可重叠在金属肽的相应限定的模板空间上,并且其中拟肽进一步包括在 至少两个元素独立地包括氨基酸残基,氨基酸侧链部分或其衍生物,限定和占据与金属肽相应元素相似的描述空间的元件。 本发明还涉及具有模板空间杂环结构的肽模拟物,包括5-,6-和8-元和5-5-和6-5-双环稠合环结构黑皮质素受体特异性肽模拟物。
-
公开(公告)号:US07326707B2
公开(公告)日:2008-02-05
申请号:US10761889
申请日:2004-01-21
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
IPC分类号: A01N43/60 , C07D241/36 , C07D241/38
CPC分类号: C07D487/04 , A61K38/12 , C07D207/16 , C07D241/04 , C07D241/08 , C07D317/72 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/12 , C07K5/0202 , C07K5/021 , C07K5/06078 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0823 , C07K5/0827 , C07K5/1008 , C07K5/101 , G06F19/16 , G06F19/706
摘要: Melanocortin receptor-specific bicyclic compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, R3 X and z are as described in the specification, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
摘要翻译: 具有以下结构的黑皮质素受体特异性双环化合物及其立体异构体和药学上可接受的盐,其中R 1,R 2,R 3 X和 z如说明书所述,其是一种或多种黑皮质素受体的激动剂,拮抗剂或混合激动剂和拮抗剂,并且可用于治疗黑皮质素受体相关疾病和病症。 还公开了含有结构(I)化合物和与其用途有关的方法的药物组合物。
-
公开(公告)号:US07718802B2
公开(公告)日:2010-05-18
申请号:US11099814
申请日:2005-04-05
申请人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu
发明人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu
IPC分类号: C07D241/04 , C07D403/06 , C07D295/023
CPC分类号: C07D241/04 , C07D403/06
摘要: Melanocortin receptor-specific compounds of the general formulas and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, L is a linker, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q includes a substituted or unsubstituted aromatic carbocyclic ring, R6, R7, y and z are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration, and optionally with one or two additional ring substituents as defined, which compounds bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要翻译: 其中J为取代或未取代的单环或双环结构的黑皮质素受体特异性化合物及其药学上可接受的盐,L为连接基,W为至少一个阳离子中心,氢键供体或氢的杂原子单元 键接受体,Q包括取代或未取代的芳族碳环,R6,R7,y和z如说明书中所定义,并且具有星号的碳原子可以具有任何立体化学构型,并且任选具有一个或两个另外的环取代基 定义为哪些化合物结合一种或多种黑皮质素受体,并且任选地是激动剂,部分激动剂,拮抗剂,反向激动剂的反向激动剂或拮抗剂,并且可用于治疗一种或多种黑皮质素受体相关 条件或障碍,以及使用本发明化合物的方法。
-
公开(公告)号:US07601753B2
公开(公告)日:2009-10-13
申请号:US11680932
申请日:2007-03-01
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
IPC分类号: A61K31/40 , C07D207/04
CPC分类号: C07D487/04 , A61K38/12 , C07D207/16 , C07D241/04 , C07D241/08 , C07D317/72 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/12 , C07K5/0202 , C07K5/021 , C07K5/06078 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0823 , C07K5/0827 , C07K5/1008 , C07K5/101 , G06F19/16 , G06F19/706
摘要: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
摘要翻译: 具有以下结构的黑皮质素受体特异性吡咯烷化合物及其立体异构体和药学上可接受的盐,其中R 1,R 2和R 3如说明书中所述,优选其中R 3是具有至少一个取代或未取代的苯基的D-氨基酸或 并且其中R 3任选地进一步包括胺封端基团或一至三个另外的氨基酸残基,任选地具有胺封端基团,所述化合物是一种或多种黑皮质素受体的激动剂,拮抗剂或混合激动剂和拮抗剂,以及 可用于治疗黑皮质素受体相关疾病和病症。 还公开了结构(I)化合物的合成方法,含有结构(I)化合物的药物组合物及其使用方法。
-
公开(公告)号:US07709484B1
公开(公告)日:2010-05-04
申请号:US11110060
申请日:2005-04-19
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Bolun Hu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Bolun Hu , Ramesh Rajpurohit
IPC分类号: A61K31/497 , C07D241/04 , C07D403/04 , C07D405/04 , C07D295/04
CPC分类号: C07D241/04 , C07D401/12 , C07D403/06 , C07D403/12
摘要: A substituted piperazine compound having the structure I: or the structure IX: or an enantomeric, stereoisomeric or diastereomeric form of the foregoing, and pharmaceutically acceptable salts thereof, where J, L, Q, W, A, R6, R7, z and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration, which compounds bind to one or more melanocortin receptors and may be employed in pharmaceutical preparations for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要翻译: 其中J,L,Q,W,A,R6,R7,z和y具有结构I或结构IX的取代哌嗪化合物或其前体的烯醇,立体异构体或非对映体形式及其药学上可接受的盐 标记有星号的碳原子可以具有任何立体化学构型,该化合物结合一种或多种黑皮质素受体并可用于治疗一种或多种黑皮质素受体相关病症或病症的药物制剂中 以及使用本发明化合物的方法。
-
公开(公告)号:US07354923B2
公开(公告)日:2008-04-08
申请号:US10762079
申请日:2004-01-21
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
IPC分类号: A61K31/497 , C07D403/04
CPC分类号: C07D401/12 , A61K38/00 , C07D241/04 , C07D241/08 , C07D403/06 , C07D403/12 , C07D417/12 , C07D487/04 , C07K5/0202 , C07K5/021 , C07K5/06078 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0823 , C07K5/0827 , C07K5/1008 , C07K5/101
摘要: Melanocortin receptor-specific piperazine or ketopiperazine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where X is CH2 or C═O, R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group, a second amino acid residue or a second amino acid residue with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
摘要翻译: 具有以下结构的黑皮质素受体特异性哌嗪或酮哌嗪化合物及其立体异构体和药学上可接受的盐,其中X为CH 2或CO,R 1,R 2 R 3和R 3 3如说明书中所述,优选其中R 3为具有至少一个取代或未取代的苯基或萘基芳基的D-氨基酸 环,并且其中R 3 3任选地进一步包括胺封端基团,第二氨基酸残基或具有胺封端基团的第二氨基酸残基,所述化合物是激动剂,拮抗剂或混合激动剂和拮抗剂 一种或多种黑皮质素受体,并且可用于治疗黑皮质素受体相关疾病和病症。 还公开了结构(I)化合物的合成方法,含有结构(I)化合物的药物组合物及其使用方法。
-
公开(公告)号:US07964601B2
公开(公告)日:2011-06-21
申请号:US12131822
申请日:2008-06-02
申请人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu , Papireddy Purma , Annette M. Shadiack , Kevin D. Burris
发明人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu , Papireddy Purma , Annette M. Shadiack , Kevin D. Burris
IPC分类号: A61K31/497 , C07D403/06 , C07D241/04 , C07D241/06
CPC分类号: C07D403/10 , C07D241/04 , C07D403/06
摘要: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要翻译: 结构I通式的黑皮质素受体特异性化合物:其中X,R1,R2a,R2b,R3,R4a,R4b,R5a和R5b如本说明书中所定义,该化合物以高亲和力结合一种或多种黑皮质素 受体,并且任选地是激动剂,拮抗剂,反向激动剂的反向激动剂或拮抗剂,并且可以用于治疗一种或黑皮质素受体相关病症或病症,以及使用本发明化合物的方法。
-
公开(公告)号:US07456184B2
公开(公告)日:2008-11-25
申请号:US10837519
申请日:2004-04-30
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit , Annette M. Shadiack , Papireddy Purma , Kevin D. Burris
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit , Annette M. Shadiack , Papireddy Purma , Kevin D. Burris
IPC分类号: A61K31/497 , C07D403/02
CPC分类号: C07D403/10 , C07D241/04 , C07D403/06
摘要: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要翻译: 结构I的通式的黑皮质素受体特异性化合物:其中X,R 1,R 2a,R 2b,R SUB R 3,R 4a,R 4b,R 5a和R 5b如本文所定义。 说明书,该化合物以高亲和力结合一种或多种黑皮质素受体,并且任选地是反向激动剂的激动剂,拮抗剂,反向激动剂或拮抗剂,并且可用于治疗一种或黑皮质素受体相关病症或 病症和使用本发明化合物的方法。
-
公开(公告)号:US20080234289A1
公开(公告)日:2008-09-25
申请号:US12131822
申请日:2008-06-02
申请人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu , Papireddy Purma , Annette M. Shadiack , Kevin D. Burris
发明人: Shubh D. Sharma , Yi-Qun Shi , Ramesh Rajpurohit , Zhijun Wu , Papireddy Purma , Annette M. Shadiack , Kevin D. Burris
IPC分类号: A61K31/495 , C07D241/04 , A61K31/496 , A61P3/04 , C07D403/06
CPC分类号: C07D403/10 , C07D241/04 , C07D403/06
摘要: A melanocortin receptor-specific compound of the general formula of structure I: where X, R1, R2a, R2b, R3, R4a, R4b, R5a and R5b are as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要翻译: 结构I的通式的黑皮质素受体特异性化合物:其中X,R 1,R 2a,R 2b,R SUB R 3,R 4a,R 4b,R 5a和R 5b如本文所定义。 说明书,该化合物以高亲和力结合一种或多种黑皮质素受体,并且任选地是反向激动剂的激动剂,拮抗剂,反向激动剂或拮抗剂,并且可用于治疗一种或黑皮质素受体相关病症或 病症和使用本发明化合物的方法。
-
公开(公告)号:US07189755B2
公开(公告)日:2007-03-13
申请号:US10776657
申请日:2004-02-10
申请人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
发明人: Shubh D. Sharma , Yi-Qun Shi , Zhijun Wu , Ramesh Rajpurohit
IPC分类号: A61K31/4025 , C07D207/04
CPC分类号: C07D487/04 , A61K38/12 , C07D207/16 , C07D241/04 , C07D241/08 , C07D317/72 , C07D401/12 , C07D403/06 , C07D403/12 , C07D417/12 , C07K5/0202 , C07K5/021 , C07K5/06078 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0823 , C07K5/0827 , C07K5/1008 , C07K5/101 , G06F19/16 , G06F19/706
摘要: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
摘要翻译: 具有以下结构的黑皮质素受体特异性吡咯烷化合物及其立体异构体和药学上可接受的盐,其中R 1,R 2和R 3是 如说明书中所述,优选其中R 3是具有至少一个取代或未取代的苯基或萘基芳环的D-氨基酸,并且其中R 3'任选地进一步包括 胺封端基团或一至三个另外的氨基酸残基,任选具有胺封端基团,该化合物是一种或多种黑皮质素受体的激动剂,拮抗剂或混合激动剂和拮抗剂,并且可用于治疗黑皮质素受体相关 疾病和病症。 还公开了结构(I)化合物的合成方法,含有结构(I)化合物的药物组合物及其使用方法。
-
-
-
-
-
-
-
-
-